CARBINOXAMINE MALEATE SALT Chemical Properties

Melting point:

116-1180C

storage temp. 

Keep in dark place,Sealed in dry,Room Temperature

Water Solubility 

Completely soluble in water

solubility 

Chloroform: Slightly Soluble; Methanol: Slightly Soluble

form 

Solid

color 

White to Almost white

Merck 

14,1799

InChIKey

GVNWHCVWDRNXAZ-BTJKTKAUSA-N

CAS DataBase Reference

3505-38-2(CAS DataBase Reference)

EPA Substance Registry System

Ethanamine, 2-[(4-chlorophenyl)-2-pyridinylmethoxy]-N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (3505-38-2)

Safety Information

Hazard Codes 

T

Risk Statements 

25-36/37/38

Safety Statements 

26-36/37/39-45

RIDADR 

3249

WGK Germany 

3

RTECS 

US6350000

HazardClass 

6.1(b)

PackingGroup 

III

HS Code 

2933399090

Toxicity

LD50 in mice (mg/kg): 166 i.p. (Cahen)

CARBINOXAMINE MALEATE SALT Usage And Synthesis

Description

Carbinoxamine is a competitive histamine H₁ receptor antagonist (K_i = 2.3 nM) and first generation antihistamine. It also competes with [³H]diltiazem, an L-type calcium channel blocker, for binding to the benzothiazepine site on rat cardiomyocytes (K_i = 1.08 nM). Carbinoxamine decreases negative inotropic activity in isolated guinea pig left atria by 76% (EC₅₀ = 250 nM) and negative chronotropic activity in guinea pig spontaneously beating isolated right atria (EC₅₀s = 250 and 480 nM, respectively) by 48% compared with control. Formulations containing carbinoxamine have been used in the treatment of allergic rhinitis.

Chemical Properties

Off-White Solid

Originator

Clistin,McNeil,US,1953

Uses

Analgesic and anti-inflammatory compound

Uses

antihistaminic

Definition

ChEBI: The maleic acid salt of carbinoxamine. An ethanolamine-type antihistamine, used for treating hay fever, as well as mild cases of Parkinson's disease.

Manufacturing Process

As described in US Patent 2,800,485 a solution of p-chlorophenylmagnesium bromide is prepared by adding dropwise a solution of 230 g (1.2 mols) of p-bromochlorobenzene in 900 cc of anhydrous ether to 26.7 g (1.1 g-atoms) of magnesium suspended in 100 cc of anhydrous ether containing a small crystal of iodine. To this solution, 107 g (1 mol) of 2-pyridinealdehyde are added slowly with stripping at a rate to maintain refluxing. The reaction mixture is then stirred for one hour at room temperature. The mixture is then poured onto an equal volume of crushed ice and water and acidified with concentrated hydrochloric acid. The ether layer is removed. The aqueous layer is made basic with ammonia and extracted with ether. The ether solution is evaporated and the residue dried by addition of benzene and removal by distillation to give 208 g (95%) of solid alpha-(p-chlorophenyl)-2-pyridinemethanol melting at 78° to 80°C. The p-chlorophenyl pyridinemethanol may alternatively be prepared from 4-chloroacetophenone, pyridine and granular aluminum as described in US Patent 2,606,195. In either case, the synthesis then proceeds as described in US Patent 2,800,485.
A solution of 219 g (1 mol) of α-(p-chlorophenyl)-2-pyridinemethanol in one liter of dry toluene is heated to 100°C with stirring. Twenty-three grams (1 g-atom) of sodium are then added in portions. After all the sodium has reacted, a dried solution of 2-dimethylaminoethyl chloride in benzene is added. This benzene solution is prepared by dissolving 173 g (1.2 mols) of 2- dimethylaminoethyl chloride hydrochloride in the minimum amount of water, adding 500 cc of benzene followed by 300 g of sodium carbonate decahydrate, stirring, separating the benzene layer and drying.
The mixture is refluxed with stirring for ten hours, cooled and filtered. The filtrate is extracted three times with 200 cc portions of 6 N acetic acid. The aqueous acetic acid solution is then made strongly basic with 10% sodium hydroxide solution, and extracted three times with 200 cc portions of ether. The ether extract is dried with anhydrous sodium sulfate, stirred with 5 g of activated carbon and filtered to provide 2-[p-chloro-α(2-dimethylaminoethoxy) benzyl]pyridine in solution. Addition of a solution of 116 g (1 mol) of maleic acid in 1,500 cc of ether gives 323 g (79%) of solid which, on recrystallization from ethyl acetate, gives white solid 2-[p-chloro-α(2-dimethylaminoethoxy) benzyl]pyridine maleate melting at 117° to 119°C.

brand name

Clistin (Ortho- McNeil).

Therapeutic Function

Antihistaminic

General Description

Carbinoxamine is availableas a bitter bimaleate salt, (d, l)-2-[p-chloro- -[2-(dimethylamino)ethoxy]benzyl]pyridine bimaleate (Clistin), which isa white crystalline powder that is very soluble in water andfreely soluble in alcohol and in chloroform. The pH of a 1%solution is between 4.6 and 5.1.
Carbinoxamine is a potent antihistaminic and is availableas the racemic mixture. It differs structurally from chlorpheniramineonly in having an oxygen atom separate theasymmetric carbon atom from the aminoethyl side chain. Themore active levo isomer of carbinoxamine has the (S) absoluteconfiguration and can be superimposed on the moreactive dextro isomer (S configuration) of chlorpheniramine.

CARBINOXAMINE MALEATE SALT(3505-38-2)Related Product Information

• carbinoxamine
• Lorlatinib (PF-06463922)
• Trimebutine maleate
• Chlorphenamine maleate
• Enalapril maleate
• Fenasi
• Flurbiprofen
• 1-PYRIDIN-2-YL-ETHANOL
• 2-(4-Chlorobenzyl)pyridine
• 2-PYRIDINEMETHANOL HYDROCHLORIDE
• alpha-(4-chlorophenyl)pyridine-2-methanol
• CARBINOXAMINE MALEATE SALT
• CHEMBRDG-BB 9070890